JP7499028B2 - 内服用医薬組成物 - Google Patents
内服用医薬組成物 Download PDFInfo
- Publication number
- JP7499028B2 JP7499028B2 JP2019238439A JP2019238439A JP7499028B2 JP 7499028 B2 JP7499028 B2 JP 7499028B2 JP 2019238439 A JP2019238439 A JP 2019238439A JP 2019238439 A JP2019238439 A JP 2019238439A JP 7499028 B2 JP7499028 B2 JP 7499028B2
- Authority
- JP
- Japan
- Prior art keywords
- itopride
- pharmaceutical composition
- gastrointestinal motility
- salt
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 claims description 38
- 229960005302 itopride Drugs 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 34
- 230000005176 gastrointestinal motility Effects 0.000 claims description 33
- 230000003213 activating effect Effects 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 238000013329 compounding Methods 0.000 claims 1
- 229940069428 antacid Drugs 0.000 description 17
- 239000003159 antacid agent Substances 0.000 description 17
- 239000008203 oral pharmaceutical composition Substances 0.000 description 17
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 15
- 230000001458 anti-acid effect Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 230000030136 gastric emptying Effects 0.000 description 10
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 229960002925 clonidine hydrochloride Drugs 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- -1 inorganic acid salts Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940008027 aluminum hydroxide / magnesium carbonate Drugs 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 238000003835 carbonate co-precipitation Methods 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000030135 gastric motility Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- HUSUHZRVLBSGBO-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydroxide Chemical compound O.[Ca+2].OP([O-])([O-])=O HUSUHZRVLBSGBO-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
項1. (A)イトプリド及び/又はその塩、並びに(B)制酸剤を含有する、内服用医薬組成物。
項2. 前記(A)成分100重量部当たり、前記(B)成分を総量で1~5000重量部含む、項1に記載の内服用医薬組成物。
項3. 前記(B)成分が、炭酸水素ナトリウムである、項1又は2に記載の内服用医薬組成物。
項4. イトプリド及び/又はその塩の消化管運動賦活作用を増強する方法であって、
内服用医薬組成物に、イトプリド及び/又はその塩と共に、制酸剤を配合する、消化管運動賦活作用増強方法。
本発明の内服用医薬組成物は、イトプリド及び/又はその塩(「(A)成分」と表記することもある)、並びに制酸剤(「(B)成分」と表記することもある)を含有することを特徴とする。以下、本発明の内服用医薬組成物について詳述する。
本発明の内服用医薬組成物は、(A)成分として、イトプリド及び/又はその塩を含有する。イトプリドは、ドパミン受容体に作用してアセチルコリンの遊離を促進し、またアセチルコリンの分解を抑制することにより消化管運動を賦活化させることが知られている公知の化合物である。
本発明の内服用医薬組成物は、(B)成分として、制酸剤を含有する。イトプリド及び/又はその塩と制酸剤と併用することによって、イトプリド及び/又はその塩の消化管運動賦活作用を飛躍的に増強させることができる。
本発明の内服用医薬組成物には、前述する成分以外に、必要に応じて、他の薬理成分を含んでいてもよい。このような薬理成分の種類については、特に制限されないが、例えば、消炎鎮痛剤、消化剤、鎮痙剤、粘膜修復剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、催眠鎮静剤、抗ヒスタミン剤、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、プロトンポンプ阻害薬、生薬、生薬エキス、カフェイン類、メントール類、ポリフェノール等が挙げられる。これらの薬理成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの薬理成分の含有量については、使用する薬理成分の種類や内服用医薬組成物の剤型等に応じて適宜設定すればよい。
本発明の内服用医薬組成物の剤型については、特に制限されず、固体状製剤、半固体状製剤、又は液体状製剤のいずれであってもよい。
本発明の内服用医薬組成物は、イトプリド及び/又はその塩の消化管運動賦活作用が増強して発揮されるので、消化管運動賦活化によって予防又は改善できる疾患や症状に適用される。このような疾患や症状としては、具体的には、機能性ディスペプシア又は慢性胃炎における消化器症状(腹部膨満感、上腹部痛、食欲不振、胸やけ、悪心、嘔吐等)、胃痛等が挙げられる。
本発明は、更に、イトプリド及び/又はその塩の消化管運動賦活作用を増強する方法であって、内服用医薬組成物に、イトプリド及び/又はその塩と共に、制酸剤を配合することを特徴とする消化管運動賦活作用増強方法を提供する。
9週齢の雄性ラット(Slc:Wistar系、日本エスエルシー株式会社)を、無処置群、コントロール群、及び試験群(実施例1及び比較例1~2)の5群(1群当たり10~13匹)に分けた。各群のラットを5日~1週間飼育して馴化させた後に以下の条件で試験を行った。
約24時間絶食させた後に、生理食塩水(1ml/kg)を皮下投与した。生理食塩水投与の10分後に0.1重量%カルボキシメチルセルロース水溶液(以下、CMC液)5ml/kg(ラット体重)となる用量で経口投与した。CMC液投与の20分後に、100個のガラスビーズ(直径750~1000μm)を含む蒸留水1mlを経口投与した。ガラスビーズ投与の60分後にラットの胃を摘出し、胃内に残存するガラスビーズを計数し、胃排出率を求めた。
約24時間絶食させた後に、消化管運動抑制作用のあるクロニジン塩酸塩(4μg/kg;投与液量は1ml/kg)を皮下投与した。クロニジン塩酸塩投与の10分後にCMC液5ml/kg(ラット体重)となる用量で経口投与した。CMC液投与の20分後に、100個のガラスビーズ(直径750~1000μm)を含む蒸留水1mlを経口投与した。ガラスビーズ投与の60分後にラットの胃を摘出し、胃内に残存するガラスビーズを計数し、胃排出率を求めた。
約24時間絶食させた後に、消化管運動抑制作用のあるクロニジン塩酸塩(4μg/kg;投与液量は1ml/kg)を皮下投与した。クロニジン塩酸塩の投与の10分後に、表1に示す成分を所定の投与量となるようにCMC液に添加して作製した試験液を5ml/kg(ラット体重)となる用量で経口投与した。試験液投与の20分後に、100個のガラスビーズ(直径750~1000μm)を含む蒸留水1mlを経口投与した。ガラスビーズ投与の60分後にラットの胃を摘出し、胃内に残存するガラスビーズを計数し、胃排出率を求めた。
表2及び3に示す組成の顆粒剤、並びに表4に示す組成の液剤を調製した。これらの製剤は、イトプリド塩酸塩と制酸剤の相乗的作用によって、格段に優れた消化管運動賦活作用を発揮できる。
Claims (2)
- (A)イトプリド及び/又はその塩、並びに(B)炭酸水素ナトリウムを含有し、前記(A)成分100重量部当たり前記(B)成分を総量で500~5000重量部含む、内服用医薬組成物。
- イトプリド及び/又はその塩の消化管運動賦活作用を増強する方法であって、
内服用医薬組成物に、イトプリド及び/又はその塩と共に、イトプリド及び/又はその塩100重量部当たり炭酸水素ナトリウムを500~5000重量部配合する、消化管運動賦活作用増強方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019238439A JP7499028B2 (ja) | 2019-12-27 | 2019-12-27 | 内服用医薬組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019238439A JP7499028B2 (ja) | 2019-12-27 | 2019-12-27 | 内服用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021107333A JP2021107333A (ja) | 2021-07-29 |
JP7499028B2 true JP7499028B2 (ja) | 2024-06-13 |
Family
ID=76967672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019238439A Active JP7499028B2 (ja) | 2019-12-27 | 2019-12-27 | 内服用医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7499028B2 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006134611A1 (en) | 2005-06-16 | 2006-12-21 | Hetero Drugs Limited | Compositions of antiulcerative substituted benzimidazoles |
JP2010030963A (ja) | 2008-07-30 | 2010-02-12 | Kowa Co | 消化管運動賦活調整剤 |
JP2014193832A (ja) | 2013-03-29 | 2014-10-09 | Kobayashi Pharmaceutical Co Ltd | モサプリドと制酸剤とを含有する医薬組成物 |
WO2018151580A1 (ko) | 2017-02-20 | 2018-08-23 | 주식회사 씨티씨바이오 | 이토프리드 염산염을 포함하는 속효성과 지속성을 갖는 약학적 제제 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08259445A (ja) * | 1995-01-27 | 1996-10-08 | Takeda Chem Ind Ltd | 胃排出能改善性医薬組成物 |
-
2019
- 2019-12-27 JP JP2019238439A patent/JP7499028B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006134611A1 (en) | 2005-06-16 | 2006-12-21 | Hetero Drugs Limited | Compositions of antiulcerative substituted benzimidazoles |
JP2010030963A (ja) | 2008-07-30 | 2010-02-12 | Kowa Co | 消化管運動賦活調整剤 |
JP2014193832A (ja) | 2013-03-29 | 2014-10-09 | Kobayashi Pharmaceutical Co Ltd | モサプリドと制酸剤とを含有する医薬組成物 |
WO2018151580A1 (ko) | 2017-02-20 | 2018-08-23 | 주식회사 씨티씨바이오 | 이토프리드 염산염을 포함하는 속효성과 지속성을 갖는 약학적 제제 |
Non-Patent Citations (8)
Title |
---|
Drug Design, Development and Therapy,2016年,10,pp.4061-4071 |
Indian Journal of Pharmaceutical Education and Research,2015年,49(2),pp.158-167 |
International Journal of Pharmacy and Biological Sciences,2018年,8(2),pp.491-503 |
International Journal of Pharmacy and Pharmaceutical Sciences,2010年,2(1),pp.53-65 |
International Journal of Pharmacy and Pharmaceutical Sciences,2014年,6(11),pp.338-343 |
Journal of Drug Delivery & Therapeutics,2013年,3(4),pp.222-228 |
RJPBCS,2010年,1(2),pp.137-142 |
World Journal of Pharmacy and Pharmaceutical Sciences,2015年,4(7),pp.823-834 |
Also Published As
Publication number | Publication date |
---|---|
JP2021107333A (ja) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5442178B2 (ja) | ロキソプロフェン含有経口用組成物 | |
JP2016155853A (ja) | ロキソプロフェン含有医薬組成物 | |
JP6192751B2 (ja) | ロキソプロフェン含有経口用組成物5 | |
JP2010168373A (ja) | ロキソプロフェン含有医薬組成物 | |
US3094464A (en) | Aspirin-antacid polysiloxane tablet | |
JPH07507293A (ja) | ヒスタミンh↓2−受容体アンタゴニストおよび陽イオン交換体複合体による組成物 | |
JP7499028B2 (ja) | 内服用医薬組成物 | |
JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
JPH0656677A (ja) | 制酸剤組成物 | |
JP6940265B2 (ja) | 止瀉剤組成物 | |
JP6940264B2 (ja) | 止瀉剤組成物 | |
CN112933091B (zh) | 一种抗胃酸类疾病的药物组合物及应用 | |
JP7170437B2 (ja) | 内服用医薬組成物 | |
JP2023173771A (ja) | 内服用医薬組成物 | |
RU2751351C2 (ru) | Пероральный препарат ибупрофена | |
JPH0899890A (ja) | 胃腸内服液 | |
KR101685710B1 (ko) | 해열 진통 조성물 | |
JP4444721B2 (ja) | 医薬組成物 | |
JP7499026B2 (ja) | 内服用医薬組成物 | |
JP2007137896A (ja) | イブプロフェン含有医薬製剤 | |
JP6753661B2 (ja) | 止瀉剤組成物 | |
BRPI0621391A2 (pt) | combinação sinérgica de inibidores de receptores h2, silicone inerte e um complexo de aluminato de hidroximagnésio | |
KR960011773B1 (ko) | 궤양의 예방 및 치료용 의약 조성물 | |
Shutkin | GLYCOPYRROLATE IN CLINICAL PRACTICE. | |
CA2602078A1 (en) | Acute and chronic heartburn composition and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221118 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240603 |